ClinicalTrials.gg
CompletedNCT04137224Updated Feb 5, 2024Results posted

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

A Phase 2 interventional study of IgPro20 and IgPro10 in Diffuse Cutaneous Systemic Sclerosis, sponsored by CSL Behring. Completed at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Scleroderma, Diffuse with a site in Poland — 4 open to participants now, 10 under way, 2 of them phase 3. Scleroderma, Diffuse · Poland.

Enrollment
16th of 18
27 · median 108
Started
2019
with 1 other
Phase 2
13 of 19
2 open now
Registered
6th of 19
by date
Lead sponsor
2 of 19
CSL Behring

Among the 19 studies in Scleroderma, Diffuse with a site in Poland, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2019, is one of 13 in phase 2, and was the 6th registered.

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

Browse Scleroderma, Diffuse studies →

Open to participants now

4 of the 19 studies in Scleroderma, Diffuse with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Scleroderma, Diffuse with a site in Poland, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized, open-label, crossover study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in participants with diffuse cutaneous systemic sclerosis (dcSSc). The pharmacokinetic study aims to evaluate the relative bioavailability of IgPro20, and characterize pharmacokinetics of IgPro20 and IgPro10, respectively, in participants with dcSSc. Safety, tolerability, and pharmacokinetics of IgPro10 will also be evaluated.

03

Conditions studied

  • Diffuse Cutaneous Systemic Sclerosis

Browse trials for

Keywords

  • scleroderma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years (male or female) at time of providing written
  • Documented diagnosis of systemic sclerosis (scleroderma) according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria 2013 (diffuse cutaneous form of SSc).
  • Modified Rodnan Skin Score (mRSS) ≥ 15 and ≤ 45 at screening
  • Disease duration ≤ 5 years defined as the time from the first non-Raynaud's phenomenon manifestation
  • Capable of providing written informed consent and willing and able to adhere to all protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Primary rheumatic disease other than dcSSc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disorder, polymyositis, dermatomyositis, as determined by the investigator. Note: Participants with fibromyalgia, secondary Sjogren's syndrome, and scleroderma-associated myopathy at screening are not excluded
  • Participants has mRSS > 2 at the potential subcutaneous (SC) injection sites
  • History of skin condition precluding SC infusion, or clinical signs and symptoms of a chronic skin disease other than systemic sclerosis or skin manifestation of an allergic disease or other dermatological conditions that would interfere with trial assessments or compromise safety (eg, dermatitis, eczema, psoriasis)
  • Participants has clinical signs and symptoms of skin irritation (eg, pruritus, burning, erythema) or hypo/ hyperpigmentation (eg, scars, tattoos) at the potential SC injection sites
  • Significant pulmonary arterial hypertension as documented by mean pulmonary arterial pressure > 30 mmHg on right heart catheterization requiring SC or IV prostacyclin or use of dual oral therapies
  • Forced vital capacity \< 50% predicted or a diffusing capacity of the lung for carbon dioxide (DLCO) ≤ 40% predicted (corrected for )
  • A female who is pregnant, breastfeeding, or is a woman of who does not agree to use acceptable methods of ; a male who does agree to use acceptable methods of contraception.
  • Evidence of chronic kidney disease with an estimated (eGFR) \< 45 mL/min/1.73m2 or if participants are receiving dialysis. Participants with current confirmed diagnosis of diabetes mellitus requiring medication with an eGFR \< 90 ml/min/1.73m2
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Sequence A (IgPro20/IgPro10)

    Participants received IgPro20 of a total dose of 0.5 grams per kilogram (g/kg) over 2 sessions per week as a subcutaneous (SC) injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2 to 5 sessions on consecutive days every 4 weeks as an intravenous (IV) infusion for up to 16 weeks in Treatment Period 2.

    Biological: IgPro20 · Biological: IgPro10

  • Experimental
    Sequence B (IgPro10/IgPro20)

    Participants received IgPro10 of a total dose of 2 g/kg over 2 to 5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.

    Biological: IgPro20 · Biological: IgPro10

Interventions

  • BiologicalIgPro20

    Human normal immunoglobulin for subcutaneous administration

    Also known as: Hizentra

  • BiologicalIgPro10

    Human normal immunoglobulin for intravenous administration

    Also known as: Privigen

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Adverse Event (AE) for IgPro20

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

    Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)

  2. Percentage of Participants With at Least One AE for IgPro20

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

    Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)

  3. Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) for IgPro20

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

    Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)

  4. Percentage of Participants With at Least One TEAE for IgPro20

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

    Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)

  5. Number of Participants With at Least One Serious Adverse Event (SAE) for IgPro20

    An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

    Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)

  6. Percentage of Participants With at Least One SAE for IgPro20

    An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

    Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)

  7. Number of Participants With at Least One Adverse Event of Special Interest (AESI) for IgPro20

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.

    Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)

  8. Percentage of Participants With at Least One AESI for IgPro20

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  9. Number of Participants With AEs Categorized as Infusion Site Reactions (ISRs) for IgPro20

    ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  10. Percentage of Participants With AEs Categorized as ISRs for IgPro20

    ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  11. Rate of ISRs Per Infusion for IgPro20

    ISR rate per infusion = total number of ISRs across all participants while on IgPro20 / total number of IgPro20 Infusions across all participants. ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions NEC', 'Infusion site reactions', or 'Injection site reactions'

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  12. Time to Onset of ISRs for IgPro20

    ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'. Time to onset of ISR since the start of the treatment period was reported.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  13. Duration of ISRs for IgPro20

    ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  14. Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro20

    Abnormality criteria:Hematology-Hemoglobin:\<10 g/dL;Platelet count:\<75x10\^9/L or \>500x10\^9/L;White Blood Cell Count:\<3x10\^9/L or \>16x10\^9/L;Neutrophils:absolute \<1.5x10\^9/L,differential \<40%;Lymphocytes:absolute \<0.8x10\^9/L,differential \<10 or \>50%; Biochemistry-Bilirubin:\>1.5xupper limit of normal (ULN);Alkaline phosphatase:\>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):\>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):\>3xULN;Screening:AST/ALT \>3xULN and Total Bilirubin \>2xULN;Urea nitrogen:\>2.5xULN; Creatinine, serum\>1.5xbaseline assessment or change \>0.3mg/dL since last visit;Glucose,blood (non-fasting):\<55/\>160mg/dL;Calcium:\<7/\>11.5mg/dL;Total protein: \<5/\>9g/dL; Albumin:\<3g/dL;Sodium:\<130/\>150mmol/L;Potassium:\<3/\>5.5mmol/L; Uric acid,serum:\>10mg/dL Males,\>8mg/dL Females;Gamma Glutamyl Transpeptidase:\>2.5xULN; Phosphorus,inorganic:\<2.5/\>5mg/dL;Lactate dehydrogenase:\>3xULN;Urinalysis-Protein:\>20mg/dL.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  15. Number of Participants With Clinically Significant Changes in Vital Signs for IgPro20

    Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): \<100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase \>10 from reference visit; Diastolic BP: \<50 mmHg or ≥90 mmHg or ≥90 mmHg and increase \>10 from reference visit; Pulse rate: \<50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase \>15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: \> 39-degree Celsius (°C ) or \<35°C (oral, tympanic, axilla or forehead).

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  16. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters for IgPro20

    Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): \>500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline \< 60 msec; QTcF: increase from baseline ≥ 60.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  17. Number of Participants With Clinically Significant Abnormalities in Pulmonary Function Tests (PFTs) for IgPro20

    PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than10 percentage points from the reference visit.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

Secondary outcomes

  1. Relative Bioavailability (%F) of IgPro20

    Relative bioavailability was calculated using Mixed Model Repeated Measures on Log-transformed Dose-normalized area under the curve to the end of the dosing period \[AUC0-tau\] following administration of the first dose of IgPro20 in the last week of dosing for Sequence A and / or Sequence B. Relative Bioavailability= (AUCtau IgPro20 (SC)/dose of IgPro20 (SC) / (AUCtau of IgPro10 (IV)/dose of IgPro10 (IV)).

    Time frame: Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)

  2. Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro20

    Time frame: Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)

  3. Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro20

    Time frame: Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)

  4. Maximum Plasma Drug Concentration (Cmax) for IgPro20

    Time frame: Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)

  5. Minimum Plasma Drug Concentration (Ctrough) for IgPro20 in Sequence A

    Time frame: Pre-injection at Weeks 5, 9, 13, and 14

  6. Minimum Plasma Drug Concentration (Ctrough) for IgPro20 in Sequence B

    Time frame: Pre-injection at Weeks 21, 25, 29, and 30

  7. Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro10

    Time frame: Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16

  8. Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro10

    Time frame: Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16

  9. Maximum Plasma Drug Concentration (Cmax) for IgPro10

    Time frame: Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16

  10. Minimum Plasma Drug Concentration (Ctrough) for IgPro10 in Sequence A

    Time frame: Pre-infusion at Weeks 21, 25 and 29

  11. Minimum Plasma Drug Concentration (Ctrough) for IgPro10 in Sequence B

    Time frame: Pre-infusion at Weeks 5, 9 and 13

  12. Number of Participants With at Least One AE for IgPro10

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  13. Percentage of Participants With at Least One AE for IgPro10

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  14. Number of Participants With at Least One TEAE for IgPro10

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  15. Percentage of Participants With at Least One TEAE for IgPro10

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  16. Number of Participants With at Least One SAE for IgPro10

    An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  17. Percentage of Participants With at Least One SAE for IgPro10

    An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  18. Number of Participants With at Least One AESI for IgPro10

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  19. Percentage of Participants With at Least One AESI for IgPro10

    AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  20. Number of Participants With AEs Categorized as ISRs for IgPro10

    ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  21. Percentage of Participants With AEs Categorized as ISRs for IgPro10

    ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  22. Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro10

    Abnormality criteria:Hematology-Hemoglobin:\<10 g/dL;Platelet count:\<75x10\^9/L or \>500x10\^9/L;White Blood Cell Count:\<3x10\^9/L or \>16x10\^9/L;Neutrophils:absolute \<1.5x10\^9/L,differential \<40%;Lymphocytes:absolute \<0.8x10\^9/L,differential \<10 or \>50%; Biochemistry-Bilirubin:\>1.5xupper limit of normal (ULN);Alkaline phosphatase:\>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):\>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):\>3xULN;Screening:AST/ALT \>3xULN and Total Bilirubin \>2xULN;Urea nitrogen:\>2.5xULN; Creatinine, serum\>1.5xbaseline assessment or change \>0.3mg/dL since last visit;Glucose,blood (non-fasting):\<55/\>160mg/dL;Calcium:\<7/\>11.5mg/dL;Total protein: \<5/\>9g/dL; Albumin:\<3g/dL;Sodium:\<130/\>150mmol/L;Potassium:\<3/\>5.5mmol/L; Uric acid,serum:\>10mg/dL Males,\>8mg/dL Females;Gamma Glutamyl Transpeptidase:\>2.5xULN; Phosphorus,inorganic:\<2.5/\>5mg/dL;Lactate dehydrogenase:\>3xULN;Urinalysis-Protein:\>20mg/dL.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  23. Number of Participants With Clinically Significant Changes in Vital Signs for IgPro10

    Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): \<100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase \>10 from reference visit; Diastolic BP: \<50 mmHg or ≥90 mmHg or ≥90 mmHg and increase \>10 from reference visit; Pulse rate: \<50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase \>15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: \> 39-degree Celsius (°C ) or \<35°C (oral, tympanic, axilla or forehead).

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  24. Number of Participants With Clinically Significant Abnormalities in ECG Parameters for IgPro10

    Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): \>500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline \< 60 msec; QTcF: increase from baseline ≥ 60.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

  25. Number of Participants With Clinically Significant Abnormalities in PFTs for IgPro10

    PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than10 percentage points from the reference visit.

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

Other outcomes

  1. Rate of ISRs Per Participant for IgPro20

    Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)

07

Results

Posted Feb 5, 2024

Participant flow

Participants were enrolled at study centers in Australia, Germany, Italy, Poland, and the United Kingdom from 19 September 2019 to 17 May 2022.

Treatment Period 1 (Week 1 to Week 16)
Participant flow — Treatment Period 1 (Week 1 to Week 16)
MilestoneSequence A (IgPro20/IgPro10)Sequence B (IgPro10/IgPro20)
Started1314
Completed1213
Not completed11
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01
Treatment Period 2 (Week 17 to Week 32)
Participant flow — Treatment Period 2 (Week 17 to Week 32)
MilestoneSequence A (IgPro20/IgPro10)Sequence B (IgPro10/IgPro20)
Started1313
Completed1312
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryNumber of Participants With at Least One Adverse Event (AE) for IgPro20

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

Time frame:
From first dose of study drug through last follow-up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event (AE) for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With at Least One Adverse Event (AE) for IgPro2099
PrimaryPercentage of Participants With at Least One AE for IgPro20

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

Time frame:
From first dose of study drug through last follow-up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One AE for IgPro20
percentage of participantsSequence A: IgPro20Sequence B: IgPro20
Percentage of Participants With at Least One AE for IgPro2069.269.2
PrimaryNumber of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) for IgPro20

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

Time frame:
From first dose of study drug through last follow-up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) for IgPro2099
PrimaryPercentage of Participants With at Least One TEAE for IgPro20

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

Time frame:
From first dose of study drug through last follow-up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One TEAE for IgPro20
percentage of participantsSequence A: IgPro20Sequence B: IgPro20
Percentage of Participants With at Least One TEAE for IgPro2069.269.2
PrimaryNumber of Participants With at Least One Serious Adverse Event (SAE) for IgPro20

An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

Time frame:
From first dose of study drug through last follow-up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Serious Adverse Event (SAE) for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With at Least One Serious Adverse Event (SAE) for IgPro2023
PrimaryPercentage of Participants With at Least One SAE for IgPro20

An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

Time frame:
From first dose of study drug through last follow-up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One SAE for IgPro20
percentage of participantsSequence A: IgPro20Sequence B: IgPro20
Percentage of Participants With at Least One SAE for IgPro2015.423.1
PrimaryNumber of Participants With at Least One Adverse Event of Special Interest (AESI) for IgPro20

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.

Time frame:
From first dose of study drug through last follow-up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event of Special Interest (AESI) for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With at Least One Adverse Event of Special Interest (AESI) for IgPro2001
PrimaryPercentage of Participants With at Least One AESI for IgPro20

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One AESI for IgPro20
percentage of participantsSequence A: IgPro20Sequence B: IgPro20
Percentage of Participants With at Least One AESI for IgPro2007.7
PrimaryNumber of Participants With AEs Categorized as Infusion Site Reactions (ISRs) for IgPro20

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With AEs Categorized as Infusion Site Reactions (ISRs) for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With AEs Categorized as Infusion Site Reactions (ISRs) for IgPro2023
PrimaryPercentage of Participants With AEs Categorized as ISRs for IgPro20

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With AEs Categorized as ISRs for IgPro20
percentage of participantsSequence A: IgPro20Sequence B: IgPro20
Percentage of Participants With AEs Categorized as ISRs for IgPro2015.423.1
PrimaryRate of ISRs Per Infusion for IgPro20

ISR rate per infusion = total number of ISRs across all participants while on IgPro20 / total number of IgPro20 Infusions across all participants. ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions NEC', 'Infusion site reactions', or 'Injection site reactions'

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Number · ISRs per infusion
Rate of ISRs Per Infusion for IgPro20
ISRs per infusionSequence A: IgPro20Sequence B: IgPro20
Rate of ISRs Per Infusion for IgPro200.00570.0360
PrimaryTime to Onset of ISRs for IgPro20

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'. Time to onset of ISR since the start of the treatment period was reported.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Median · days
Time to Onset of ISRs for IgPro20
daysSequence A: IgPro20Sequence B: IgPro20
Time to Onset of ISRs for IgPro202.0 (1 to 3)15.0 (1 to 64)
PrimaryDuration of ISRs for IgPro20

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Median · minutes
Duration of ISRs for IgPro20
minutesSequence A: IgPro20Sequence B: IgPro20
Duration of ISRs for IgPro20162.0 (162 to 162)220.0 (180 to 1170)
PrimaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro20

Abnormality criteria:Hematology-Hemoglobin:\<10 g/dL;Platelet count:\<75x10\^9/L or \>500x10\^9/L;White Blood Cell Count:\<3x10\^9/L or \>16x10\^9/L;Neutrophils:absolute \<1.5x10\^9/L,differential \<40%;Lymphocytes:absolute \<0.8x10\^9/L,differential \<10 or \>50%; Biochemistry-Bilirubin:\>1.5xupper limit of normal (ULN);Alkaline phosphatase:\>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):\>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):\>3xULN;Screening:AST/ALT \>3xULN and Total Bilirubin \>2xULN;Urea nitrogen:\>2.5xULN; Creatinine, serum\>1.5xbaseline assessment or change \>0.3mg/dL since last visit;Glucose,blood (non-fasting):\<55/\>160mg/dL;Calcium:\<7/\>11.5mg/dL;Total protein: \<5/\>9g/dL; Albumin:\<3g/dL;Sodium:\<130/\>150mmol/L;Potassium:\<3/\>5.5mmol/L; Uric acid,serum:\>10mg/dL Males,\>8mg/dL Females;Gamma Glutamyl Transpeptidase:\>2.5xULN; Phosphorus,inorganic:\<2.5/\>5mg/dL;Lactate dehydrogenase:\>3xULN;Urinalysis-Protein:\>20mg/dL.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro2000
PrimaryNumber of Participants With Clinically Significant Changes in Vital Signs for IgPro20

Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): \<100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase \>10 from reference visit; Diastolic BP: \<50 mmHg or ≥90 mmHg or ≥90 mmHg and increase \>10 from reference visit; Pulse rate: \<50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase \>15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: \> 39-degree Celsius (°C ) or \<35°C (oral, tympanic, axilla or forehead).

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With Clinically Significant Changes in Vital Signs for IgPro2000
PrimaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters for IgPro20

Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): \>500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline \< 60 msec; QTcF: increase from baseline ≥ 60.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters for IgPro2001
PrimaryNumber of Participants With Clinically Significant Abnormalities in Pulmonary Function Tests (PFTs) for IgPro20

PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than10 percentage points from the reference visit.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Pulmonary Function Tests (PFTs) for IgPro20
ParticipantsSequence A: IgPro20Sequence B: IgPro20
Number of Participants With Clinically Significant Abnormalities in Pulmonary Function Tests (PFTs) for IgPro2000
SecondaryRelative Bioavailability (%F) of IgPro20

Relative bioavailability was calculated using Mixed Model Repeated Measures on Log-transformed Dose-normalized area under the curve to the end of the dosing period \[AUC0-tau\] following administration of the first dose of IgPro20 in the last week of dosing for Sequence A and / or Sequence B. Relative Bioavailability= (AUCtau IgPro20 (SC)/dose of IgPro20 (SC) / (AUCtau of IgPro10 (IV)/dose of IgPro10 (IV)).

Time frame:
Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)
Reported as:
Geometric mean · percentage bioavailability
Relative Bioavailability (%F) of IgPro20
percentage bioavailabilitySequence A: IgPro20Sequence B: IgPro20
Relative Bioavailability (%F) of IgPro200.831 (0.7343 to 0.9396)0.698 (0.6235 to 0.7804)
SecondaryArea Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro20
Time frame:
Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)
Reported as:
Geometric mean · hours*grams per liter (h*g/L)
Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro20
hours*grams per liter (h*g/L)Sequence A: IgPro20Sequence B: IgPro20
Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro203835.68 (3394.749 to 4333.883)3581.08 (3326.635 to 3854.997)
SecondaryArea Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro20
Time frame:
Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)
Reported as:
Geometric mean · h*g/L
Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro20
h*g/LSequence A: IgPro20Sequence B: IgPro20
Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro205361.61 (4729.962 to 6077.619)4898.02 (4437.732 to 5406.046)
SecondaryMaximum Plasma Drug Concentration (Cmax) for IgPro20
Time frame:
Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)
Reported as:
Geometric mean · g/L
Maximum Plasma Drug Concentration (Cmax) for IgPro20
g/LSequence A: IgPro20Sequence B: IgPro20
Maximum Plasma Drug Concentration (Cmax) for IgPro2024.237 (21.6041 to 27.1898)23.203 (21.7278 to 24.7782)
SecondaryMinimum Plasma Drug Concentration (Ctrough) for IgPro20 in Sequence A
Time frame:
Pre-injection at Weeks 5, 9, 13, and 14
Reported as:
Geometric mean · g/L
Minimum Plasma Drug Concentration (Ctrough) for IgPro20 in Sequence A
g/LSequence A: IgPro20
Week 522.046 (16.69 to 63.70)
Week 921.950 (14.71 to 30.51)
Week 1322.354 (16.98 to 31.36)
Week 1421.814 (14.49 to 27.93)
SecondaryMinimum Plasma Drug Concentration (Ctrough) for IgPro20 in Sequence B
Time frame:
Pre-injection at Weeks 21, 25, 29, and 30
Reported as:
Geometric mean · g/L
Minimum Plasma Drug Concentration (Ctrough) for IgPro20 in Sequence B
g/LSequence B: IgPro20
Week 2120.427 (12.82 to 25.48)
Week 2521.603 (16.92 to 30.49)
Week 2921.903 (18.89 to 28.47)
Week 3020.497 (18.15 to 23.59)
SecondaryArea Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro10
Time frame:
Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16
Reported as:
Geometric mean · h*g/L
Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro10
h*g/LSequence A: IgPro10Sequence B: IgPro10
Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro1016942.66 (15097.493 to 19013.345)17672.03 (16402.479 to 19039.837)
SecondaryArea Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro10
Time frame:
Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16
Reported as:
Geometric mean · h*g/L
Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro10
h*g/LSequence A: IgPro10Sequence B: IgPro10
Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro1016520.48 (14742.232 to 18513.218)17349.72 (15917.101 to 18911.275)
SecondaryMaximum Plasma Drug Concentration (Cmax) for IgPro10
Time frame:
Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16
Reported as:
Geometric mean · g/L
Maximum Plasma Drug Concentration (Cmax) for IgPro10
g/LSequence A: IgPro10Sequence B: IgPro10
Maximum Plasma Drug Concentration (Cmax) for IgPro1047.142 (41.2538 to 53.8713)44.996 (39.2110 to 51.6340)
SecondaryMinimum Plasma Drug Concentration (Ctrough) for IgPro10 in Sequence A
Time frame:
Pre-infusion at Weeks 21, 25 and 29
Reported as:
Geometric mean · g/L
Minimum Plasma Drug Concentration (Ctrough) for IgPro10 in Sequence A
g/LSequence A: IgPro10
Week 2116.123 (9.69 to 34.70)
Week 2517.497 (8.80 to 54.96)
Week 2916.838 (8.51 to 58.16)
SecondaryMinimum Plasma Drug Concentration (Ctrough) for IgPro10 in Sequence B
Time frame:
Pre-infusion at Weeks 5, 9 and 13
Reported as:
Geometric mean · g/L
Minimum Plasma Drug Concentration (Ctrough) for IgPro10 in Sequence B
g/LSequence B: IgPro10
Week 517.104 (12.77 to 24.04)
Week 917.744 (13.92 to 23.36)
Week 1317.113 (12.89 to 25.43)
SecondaryNumber of Participants With at Least One AE for IgPro10

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One AE for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With at Least One AE for IgPro1058
SecondaryPercentage of Participants With at Least One AE for IgPro10

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One AE for IgPro10
percentage of participantsSequence A: IgPro10Sequence B: IgPro10
Percentage of Participants With at Least One AE for IgPro1038.557.1
SecondaryNumber of Participants With at Least One TEAE for IgPro10

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One TEAE for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With at Least One TEAE for IgPro1058
SecondaryPercentage of Participants With at Least One TEAE for IgPro10

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One TEAE for IgPro10
percentage of participantsSequence A: IgPro10Sequence B: IgPro10
Percentage of Participants With at Least One TEAE for IgPro1038.557.1
SecondaryNumber of Participants With at Least One SAE for IgPro10

An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One SAE for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With at Least One SAE for IgPro1011
SecondaryPercentage of Participants With at Least One SAE for IgPro10

An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One SAE for IgPro10
percentage of participantsSequence A: IgPro10Sequence B: IgPro10
Percentage of Participants With at Least One SAE for IgPro107.77.1
SecondaryNumber of Participants With at Least One AESI for IgPro10

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One AESI for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With at Least One AESI for IgPro1000
SecondaryPercentage of Participants With at Least One AESI for IgPro10

AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One AESI for IgPro10
percentage of participantsSequence A: IgPro10Sequence B: IgPro10
Percentage of Participants With at Least One AESI for IgPro1000
SecondaryNumber of Participants With AEs Categorized as ISRs for IgPro10

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With AEs Categorized as ISRs for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With AEs Categorized as ISRs for IgPro1000
SecondaryPercentage of Participants With AEs Categorized as ISRs for IgPro10

ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With AEs Categorized as ISRs for IgPro10
percentage of participantsSequence A: IgPro10Sequence B: IgPro10
Percentage of Participants With AEs Categorized as ISRs for IgPro1000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro10

Abnormality criteria:Hematology-Hemoglobin:\<10 g/dL;Platelet count:\<75x10\^9/L or \>500x10\^9/L;White Blood Cell Count:\<3x10\^9/L or \>16x10\^9/L;Neutrophils:absolute \<1.5x10\^9/L,differential \<40%;Lymphocytes:absolute \<0.8x10\^9/L,differential \<10 or \>50%; Biochemistry-Bilirubin:\>1.5xupper limit of normal (ULN);Alkaline phosphatase:\>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):\>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):\>3xULN;Screening:AST/ALT \>3xULN and Total Bilirubin \>2xULN;Urea nitrogen:\>2.5xULN; Creatinine, serum\>1.5xbaseline assessment or change \>0.3mg/dL since last visit;Glucose,blood (non-fasting):\<55/\>160mg/dL;Calcium:\<7/\>11.5mg/dL;Total protein: \<5/\>9g/dL; Albumin:\<3g/dL;Sodium:\<130/\>150mmol/L;Potassium:\<3/\>5.5mmol/L; Uric acid,serum:\>10mg/dL Males,\>8mg/dL Females;Gamma Glutamyl Transpeptidase:\>2.5xULN; Phosphorus,inorganic:\<2.5/\>5mg/dL;Lactate dehydrogenase:\>3xULN;Urinalysis-Protein:\>20mg/dL.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro1000
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs for IgPro10

Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): \<100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase \>10 from reference visit; Diastolic BP: \<50 mmHg or ≥90 mmHg or ≥90 mmHg and increase \>10 from reference visit; Pulse rate: \<50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase \>15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: \> 39-degree Celsius (°C ) or \<35°C (oral, tympanic, axilla or forehead).

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With Clinically Significant Changes in Vital Signs for IgPro1000
SecondaryNumber of Participants With Clinically Significant Abnormalities in ECG Parameters for IgPro10

Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): \>500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline \< 60 msec; QTcF: increase from baseline ≥ 60.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in ECG Parameters for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With Clinically Significant Abnormalities in ECG Parameters for IgPro1000
SecondaryNumber of Participants With Clinically Significant Abnormalities in PFTs for IgPro10

PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than10 percentage points from the reference visit.

Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in PFTs for IgPro10
ParticipantsSequence A: IgPro10Sequence B: IgPro10
Number of Participants With Clinically Significant Abnormalities in PFTs for IgPro1000
Other pre-specifiedRate of ISRs Per Participant for IgPro20
Time frame:
From first dose of study drug through last follow up visit (up to 36 weeks)

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study drug through last follow up visit (up to 36 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sequence A: IgPro200/13 (0%)2/13 (15.4%)8/13 (61.5%)
Sequence A: IgPro100/13 (0%)1/13 (7.7%)5/13 (38.5%)
Sequence B: IgPro100/14 (0%)1/14 (7.1%)8/14 (57.1%)
Sequence B: IgPro200/13 (0%)3/13 (23.1%)6/13 (46.2%)
Most frequent serious events
Most frequent serious events
EventSequence A: IgPro20Sequence A: IgPro10Sequence B: IgPro10Sequence B: IgPro20
Upper gastrointestinal haemorrhageGastrointestinal disorders1/130/130/140/13
Chest painGeneral disorders1/130/130/140/13
Chronic gastritisGastrointestinal disorders0/131/130/140/13
VomitingGastrointestinal disorders0/131/130/140/13
DehydrationMetabolism and nutrition disorders0/131/130/140/13
Myocardial infarctionCardiac disorders0/130/130/141/13
Myocardial ischaemiaCardiac disorders0/130/130/141/13
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/130/130/141/13
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/130/130/141/13
Viral InfectionInfections and infestations0/130/131/140/13
Most frequent other events
Showing 10 of 62
Most frequent other events
EventSequence A: IgPro20Sequence A: IgPro10Sequence B: IgPro10Sequence B: IgPro20
HeadacheNervous system disorders1/130/135/140/13
Abdominal painGastrointestinal disorders2/130/130/140/13
Infusion site swellingGeneral disorders0/130/130/142/13
COVID-19Infections and infestations1/130/130/142/13
DiarrhoeaGastrointestinal disorders1/130/132/140/13
NauseaGastrointestinal disorders0/130/132/141/13
ErythemaSkin and subcutaneous tissue disorders0/130/132/140/13
ToothacheGastrointestinal disorders0/131/130/141/13
VomitingGastrointestinal disorders0/130/131/141/13
Abdominal distensionGastrointestinal disorders1/130/130/140/13

Baseline characteristics

Safety analysis set included all participants who received at least 1 infusion of IgPro20 or IgPro10.

Age, Continuous
Age, Continuous(years)Sequence A (IgPro20/IgPro10)Sequence B (IgPro10/IgPro20)Total
Mean51.4 ± 12.2247.4 ± 12.9149.3 ± 12.50
Sex: Female, Male
Sex: Female, Male(Participants)Sequence A (IgPro20/IgPro10)Sequence B (IgPro10/IgPro20)Total
Female10818
Male369
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence A (IgPro20/IgPro10)Sequence B (IgPro10/IgPro20)Total
Hispanic or Latino000
Not Hispanic or Latino121426
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence A (IgPro20/IgPro10)Sequence B (IgPro10/IgPro20)Total
Race — White131326
Race — Other011
Region of Enrollment
Region of Enrollment(Participants)Sequence A (IgPro20/IgPro10)Sequence B (IgPro10/IgPro20)Total
Poland9817
United Kingdom336
Italy101
Australia022
Germany011
08

Study locations

9 sites
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Uniklinik Köln, innere Medizin
    Köln, 50937, Germany
  • ASST Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Azienda Ospedaliera Gaetano Pini
    Milano, 20122, Italy
  • Uniwersytecki Szpital Kliniczny W Bialymstoku
    Bialystok, 15-276, Poland
  • Szpital Kliniczny Jezus
    Warsaw, 02-008, Poland
  • Narodowy Instytut Geriatrii
    Warsaw, 02-637, Poland
  • The Royal Free Hospital
    London, NW3 2QG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in May 2022, 31 months.

Results were first posted in Feb 2024, 1 year 8 months after primary completion.

Of 24 phase 2 interventional studies under Scleroderma, Diffuse, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 108. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Oct 23, 2019
StartActual
Sep 19, 2019
Primary completionActual
May 17, 2022
CompletionActual
May 17, 2022
Results first posted
Feb 5, 2024
Last update
Feb 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04137224
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Oct 23, 2019
Start date
Sep 19, 2019
Primary completion
May 17, 2022
Completion
May 17, 2022
Results posted
Feb 5, 2024
Last update
Feb 5, 2024

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hizentra · IGPRO10

Start the discussion